$97.1087
-1.2413[-1.26%]
At close: Apr 24
$97.1087
0[0.00%]
PreMarket: 5:42PM EDT
Novartis Stock (NYSE:NVS), Analyst Ratings, Price Targets, Predictions
Novartis AG has a consensus price target of $32.86, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, BMO Capital, and Morgan Stanley on April 24, 2024, February 23, 2024, and January 23, 2024. With an average price target of $114.67 between BMO Capital, BMO Capital, and Morgan Stanley, there's an implied 18.08% upside for Novartis AG from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Morgan Stanley
Morgan Stanley
Wolfe Research
Exane BNP Paribas
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Novartis
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | NVS | Buy Now | Novartis | $97.11 | 19.45% | BMO Capital | Etzer Darout | $114 → $116 | Maintains | Market Perform | Get Alert |
| 02/23/2024 | NVS | Buy Now | Novartis | $97.11 | 17.39% | BMO Capital | Etzer Darout | → $114 | Initiates | → Market Perform | Get Alert |
| 01/23/2024 | NVS | Buy Now | Novartis | $97.11 | 17.39% | Morgan Stanley | Mark Purcell | → $114 | Initiates | → Equal-Weight | Get Alert |
| 09/25/2023 | NVS | Buy Now | Novartis | $97.11 | — | Morgan Stanley | Vincent Meunier | — | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/09/2022 | NVS | Buy Now | Novartis | $97.11 | — | Wolfe Research | Tim Anderson | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 12/06/2021 | NVS | Buy Now | Novartis | $97.11 | — | Exane BNP Paribas | Richard Parkes | — | Downgrade | Outperform → Neutral | Get Alert |
| 12/03/2021 | NVS | Buy Now | Novartis | $97.11 | — | Bryan Garnier | Jeanjacques Le Fur | — | Downgrade | Buy → Neutral | Get Alert |
| 09/20/2021 | NVS | Buy Now | Novartis | $97.11 | — | Deutsche Bank | Emmanuel Papadakis | — | Downgrade | Hold → Sell | Get Alert |
FAQ
What is the target price for Novartis (NVS)?
The latest price target for Novartis (NYSE: NVS) was reported by BMO Capital on April 24, 2024. The analyst firm set a price target for $116.00 expecting NVS to rise to within 12 months (a possible 19.45% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novartis (NVS)?
The latest analyst rating for Novartis (NYSE: NVS) was provided by BMO Capital, and Novartis maintained their market perform rating.
When was the last upgrade for Novartis (NVS)?
The last upgrade for Novartis AG happened on September 25, 2023 when Morgan Stanley raised their price target to N/A. Morgan Stanley previously had an underweight for Novartis AG.
When was the last downgrade for Novartis (NVS)?
The last downgrade for Novartis AG happened on May 9, 2022 when Wolfe Research changed their price target from N/A to N/A for Novartis AG.
When is the next analyst rating going to be posted or updated for Novartis (NVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating Novartis (NVS) correct?
While ratings are subjective and will change, the latest Novartis (NVS) rating was a maintained with a price target of $114.00 to $116.00. The current price Novartis (NVS) is trading at is $97.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.